Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 28, 2026International OphthalmologyOpen Access

Improvement in visual outcomes in diabetic macular edema through the reduction of macular thickness fluctuations using the 0, 19 mg fluocinolone acetonide implant

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSusana Costa PenasBPBernardete PessoaCTCarla Teixeira

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Penas et al. (2026) studied this question.

synapsesocial.com/papers/6ab9b4597822ec8fc3d8ded9https://doi.org/10.1007/s10792-026-04262-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety Outcomes of Fluocinolone Acetonide Intravitreal Implant in Refractory Diabetic Macular Edema: A Real-World Study2026
  2. 2Real-life results after the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema2024
  3. 3Fluocinolone acetonide implant in diabetic macular edema: sustained benefits and effects of following prior therapy2026
  4. 4Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study2025
  5. 5Intravitreal fluocinolone acetonide implant for diabetic macular edema – 2-year results from IDEAL, a prospective German observational study2026